Saman Jayasinghe, MD
Public Health & General Preventive Medicine · New Orleans, LANPI 1306162672
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 97.6% of the total across 56 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 15 manufacturers reported payments, led by Abbott at 54.3% of the total. 2025 is the largest year on record at $695, more than ten times the $25 reported in 2019.
Across 56 payments — averaging $29.65 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Abbott$902
- Lilly USA, LLC$241
- Exact Sciences$103
- GSK$79
- Novo Nordisk$62
- Bayer$49
- plus $224 from 9 others
What the payments were for
- Food & beverage$1,62098%
- Other$402%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Abbott | 18 | $902 |
| Lilly USA, LLC | 10 | $241 |
| Exact Sciences | 5 | $103 |
| GSK | 4 | $79 |
| Novo Nordisk | 4 | $62 |
| Bayer | 2 | $49 |
| Merck | 3 | $47 |
| Organon | 2 | $43 |
| Pfizer | 1 | $26 |
| E.r. Squibb & Sons, L.L.C. | 2 | $25 |
| Biocryst US Sales Co., LLC | 1 | $18 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 1 | $17 |
| Boehringer Ingelheim | 1 | $16 |
| AstraZeneca | 1 | $16 |
| Amgen | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- FREESTYLE LIBRE 3$614
- ZEPBOUND$105
How this compares
Too few public health & general preventive medicine providers in Louisianato place this figure against a meaningful peer group, so we don't.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| FarxigaDapagliflozin Propanediol | 26 | $18,609 |
| OzempicSemaglutide | 19 | $18,270 |
| MounjaroTirzepatide | 14 | $15,458 |
| JardianceEmpagliflozin | 14 | $12,098 |
| Tresiba Flextouch U-100Insulin Degludec | 11 | $5,946 |
| Toujeo SolostarInsulin Glargine,hum.Rec.Anlog | 11 | $4,814 |
| Insulin Lispro Kwikpen U-100Insulin Lispro | 23 | $2,639 |
| Gabapentin | 44 | $1,748 |
| Omeprazole | 58 | $1,389 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 27 | $678 |
| Esomeprazole Magnesium | 11 | $531 |
| Methocarbamol | 11 | $524 |
| Atorvastatin Calcium | 67 | $418 |
| Zolpidem Tartrate | 22 | $415 |
| Fluticasone Propionate | 19 | $395 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AstraZenecaFarxiga | $16 | $18,60926 claims |
| Novo NordiskOzempic | $62 | $18,27019 claims |
| Lilly USA, LLCMounjaro | $241 | $15,45814 claims |
| Boehringer IngelheimJardiance | $16 | $12,09814 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. There are too few public health & general preventive medicine providers in Louisianaon file to place this against a meaningful peer group, so we don't.
Other public health & general preventive medicine in New Orleans
- Steven BuddNew Orleans$456
- Moses BraimohLafayette$4K
- Keith BlackmanRiver Ridge$268
- Raoult RatardMetairie$107
- Juliette StefanskiLafayette$76
- Frank WelchMetairie$13
- William RigginsThibodaux$12
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.